Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psoriasis
Biotech
Vyne prunes psoriasis trial, but keeps faith in BET inhibitor
Vyne has given up hope of resuming a psoriasis trial of its BET inhibitor under an FDA hold, but the biotech plans to persevere with the candidate.
James Waldron
Jul 2, 2025 10:33am
Accropeutics' TYK2/JAK1 inhibitor scores phase 2 psoriasis win
May 21, 2025 6:25am
Vyne’s psoriasis drug hit with FDA hold over testicular toxicity
Apr 25, 2025 9:25am
Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial
Apr 24, 2025 4:46am
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu
Mar 10, 2025 7:30am
BMS backs out of Dupixent fight, axing asset despite phase 3 win
Feb 7, 2025 6:26am
